Patients Stopping Weight-Loss Medications Regain Weight Far More Rapidly Compared to Dieters

New research suggests that patients who stop using blockbuster weight-loss injections like Wegovy and Mounjaro can put back on lost weight far faster than those who halt conventional lifestyle plans.

Published data in a leading health publication demonstrates that while obese people frequently drop about a fifth of their total mass while on the medication, the mass is regained at an estimated rate of nearly a kilo each month after stopping.

"Individuals purchasing such drugs must be informed of the danger of quick weight regain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.

That rate of regain means a reversion to starting weight within about one and a half years.

Comparing Approaches

The analysis, which examined 37 of studies involving over 9,000 of participants, contrasted the outcomes of these new drugs with conventional dieting.

The team point out that people who shed pounds through lifestyle changes alone generally experience a slower weight regain—approximately 100 grams monthly—after stopping.

Understanding the Quick Rebound

Doctors believe the mode of action of the injections is key to understanding the accelerated regain.

The injections mimic a body's own chemical called glucagon-like peptide-1, which controls hunger.

"Artificially providing GLP-1 concentrations far above than the body's typical production could lead to the system to generate a reduced amount of its own natural hormone, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics expert.

"Discontinuation of this medication leads to appetite is uncontrolled, making overeating a significant risk."

An Ongoing Issue?

Medical guidelines suggest the jabs for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications.

A number of clinicians contend that, considering the significant potential of weight regain, the therapy is often ongoing.

This perspective is supported by drug manufacturers, who say that the findings "underscore the long-term nature of obesity," akin to managing diseases like high blood pressure.

Patient Experiences

Users who have discontinued the jabs explain a powerful return of appetite.

"I experienced something activating and I was suddenly extremely hungry," described an individual.

The struggle is compounded if individuals have not developed permanent dietary or behavioural modifications during therapy.

Widespread Use

Survey data indicate that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high.

• Adoption is greater among women than men.
• The middle-aged demographic shows the greatest usage rates.
• A large proportion obtain the drugs through private healthcare rather than the NHS.

In conclusion, researchers stress that while the jabs are powerful tools for weight loss, they are not a permanent solution and lasting health benefits likely depends on integrated lifestyle management.